Improving Intracellular Doxorubicin Delivery Through Nanoliposomes Equipped with Selective Tumor Cell Membrane Permeabilizing Short-Chain Sphingolipids

[1]  Stavroula Sofou,et al.  Antitumor efficacy following the intracellular and interstitial release of liposomal doxorubicin. , 2012, Biomaterials.

[2]  A. Eggermont,et al.  Enriching lipid nanovesicles with short‐chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  Scott E McNeil,et al.  Rapid Distribution of Liposomal Short-Chain Ceramide in Vitro and in Vivo , 2008, Drug Metabolism and Disposition.

[4]  D. Alberts,et al.  Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). , 2007, Gynecologic oncology.

[5]  S. Yusuf,et al.  Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation , 2007, International journal of nanomedicine.

[6]  A. Eggermont,et al.  Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response. , 2007, Cancer research.

[7]  G. Koning,et al.  Targeted multifunctional lipid-based nanocarriers for image-guided drug delivery. , 2007, Anti-cancer agents in medicinal chemistry.

[8]  Richard G. W. Anderson,et al.  Lipid rafts: at a crossroad between cell biology and physics , 2007, Nature Cell Biology.

[9]  S. Fleischer,et al.  Two dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots , 1970, Lipids.

[10]  Gert Storm,et al.  Coformulated N-Octanoyl-glucosylceramide Improves Cellular Delivery and Cytotoxicity of Liposomal Doxorubicin , 2005, Journal of Pharmacology and Experimental Therapeutics.

[11]  Theresa M. Allen,et al.  Determination of Doxorubicin Levels in Whole Tumor and Tumor Nuclei in Murine Breast Cancer Tumors , 2005, Clinical Cancer Research.

[12]  M. Colombini,et al.  Sphingosine Forms Channels in Membranes That Differ Greatly from Those Formed by Ceramide , 2005, Journal of bioenergetics and biomembranes.

[13]  Shelton D Caruthers,et al.  Magnetic resonance nanoparticles for cardiovascular molecular imaging and therapy , 2005, Expert review of cardiovascular therapy.

[14]  M. Hussein,et al.  Role of liposomal anthracyclines in the treatment of multiple myeloma. , 2004, Seminars in oncology.

[15]  A. Santoro,et al.  Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  S. Zerp,et al.  N-hexanoyl-sphingomyelin potentiates in vitro doxorubicin cytotoxicity by enhancing its cellular influx , 2004, British Journal of Cancer.

[17]  R. Perez-soler,et al.  Cellular pharmacology of the partially non-cross-resistant anthracycline annamycin entrapped in liposomes in KB and KB-V1 cells , 1994, Cancer Chemotherapy and Pharmacology.

[18]  M. Bally,et al.  Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia , 2004, Cancer Chemotherapy and Pharmacology.

[19]  Theresa M Allen,et al.  Rate of biodistribution of STEALTH liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity. , 2003, Biochimica et biophysica acta.

[20]  Yechezkel Barenholz,et al.  Pharmacokinetics of Pegylated Liposomal Doxorubicin , 2003, Clinical pharmacokinetics.

[21]  W. Gajewski,et al.  Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer , 2002, Expert review of anticancer therapy.

[22]  M. Masserini,et al.  Role of sphingolipids in the biogenesis of membrane domains. , 2001, Biochimica et biophysica acta.

[23]  J. Blay,et al.  Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. , 2001, European journal of cancer.

[24]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[25]  J. Kamps,et al.  Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine from immunoliposomes to colon cancer cells. , 1999, Biochimica et biophysica acta.

[26]  G. Koning,et al.  Antiproliferative effect of immunoliposomes containing 5-fluorodeoxyuridine-dipalmitate on colon cancer cells , 1999, British Journal of Cancer.

[27]  D. Gewirtz,et al.  A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. , 1999, Biochemical pharmacology.

[28]  P. Cullis,et al.  Factors influencing uptake and retention of amino-containing drugs in large unilamellar vesicles exhibiting transmembrane pH gradients. , 1999, Biochimica et biophysica acta.

[29]  S M Gruner,et al.  Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient. , 1998, Biochimica et biophysica acta.

[30]  M A Fischl,et al.  Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  R. G. Anderson.  The caveolae membrane system. , 1998, Annual review of biochemistry.

[32]  A A Bogdanov,et al.  Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. , 1994, Biochimica et biophysica acta.

[33]  Y. Barenholz,et al.  Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. , 1993, Biochimica et biophysica acta.

[34]  D. Coulter,et al.  Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. , 1992, Cancer research.

[35]  L. Huang,et al.  Stable target-sensitive immunoliposomes. , 1992, Biochemistry.

[36]  A. Gabizon.  Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. , 1992, Cancer research.

[37]  M. Bally,et al.  Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor. , 1990, Cancer letters.

[38]  D. Scudiero,et al.  New colorimetric cytotoxicity assay for anticancer-drug screening. , 1990, Journal of the National Cancer Institute.

[39]  A. Bodley,et al.  DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA. , 1989, Cancer research.

[40]  E. Jaffe,et al.  Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. , 1973, The Journal of clinical investigation.